sulopenem etzadroxil probenecid emerging drug insight and market forecast

“Sulopenem Etzadroxil/Probenecid Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about Sulopenem Etzadroxil/Probenecid for uncomplicated Urinary Tract Infection in the 7MM. A detailed picture of the Sulopenem Etzadroxil/Probenecid for uncomplicated Urinary Tract Infection in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the Sulopenem Etzadroxil/Probenecid for uncomplicated Urinary Tract Infection. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Sulopenem Etzadroxil/Probenecid market forecast, analysis for uncomplicated Urinary Tract Infection in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in uncomplicated Urinary Tract Infection.

Drug Summary

Iterum Therapeutics is developing its first compound, sulopenem, a novel penem anti-infective compound, with both an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against various gram-negative, gram-positive, and anaerobic bacteria resistant to other antibiotics. Sulopenem is an orally bioavailable, broad-spectrum penem ß-lactam antibiotic that is being developed to treat infections caused by multi-drug resistant bacteria.

Sulopenem was discovered in the laboratories of Pfizer in the 1980s and was first developed with an intravenous (IV) formulation only. The company completed an extensive pre-clinical program, followed by human studies. Later, an oral formulation was developed and tested in Phase I and Phase II trials. Sulopenem is a parenteral thiopenem with broad-spectrum antibacterial activity against most gram-positive and gram-negative bacteria. Sulopenem is not active against Pseudomonas aeruginosa. In addition, this agent is fairly stable against hydrolysis by various beta-lactamases.

Currently, Sulopenem is being investigated in Phase I clinical study after completing a Phase III clinical trial for the treatment of uUTI. This ongoing trial is a Phase I, multi-center, open-label study to evaluate the safety, tolerability, and pharmacokinetics of sulopenem and Sulopenem Etzadroxil + Probenecid in adolescent patients with bacterial infection (including uUTI). The company has recently filed NDA (November 2020) to the US FDA for oral sulopenem for the treatment of uUTI in patients with a quinolone non-susceptible pathogen, however the FDA has issued a CRL, determining that additional data are necessary to support approval for the treatment of adult women with uUTI and it can’t be approved in its present form.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Sulopenem Etzadroxil/Probenecid description, mechanism of action, dosage and administration, research and development activities in uncomplicated Urinary Tract Infection.
• Elaborated details on Sulopenem Etzadroxil/Probenecid regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Sulopenem Etzadroxil/Probenecid research and development activity in uncomplicated Urinary Tract Infection details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Sulopenem Etzadroxil/Probenecid.
• The report contains forecasted sales of Sulopenem Etzadroxil/Probenecid for uncomplicated Urinary Tract Infection till 2032.
• Comprehensive coverage of the late-stage emerging therapies for uncomplicated Urinary Tract Infection.
• The report also features the SWOT analysis with analyst views for Sulopenem Etzadroxil/Probenecid in uncomplicated Urinary Tract Infection.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Sulopenem Etzadroxil/Probenecid Analytical Perspective by DelveInsight

• In-depth Sulopenem Etzadroxil/Probenecid Market Assessment

This report provides a detailed market assessment of Sulopenem Etzadroxil/Probenecid in uncomplicated Urinary Tract Infection in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• Sulopenem Etzadroxil/Probenecid Clinical Assessment

The report provides the clinical trials information of Sulopenem Etzadroxil/Probenecid for uncomplicated Urinary Tract Infection covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for uncomplicated Urinary Tract Infection is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Sulopenem Etzadroxil/Probenecid dominance.
• Other emerging products for uncomplicated Urinary Tract Infection are expected to give tough market competition to Sulopenem Etzadroxil/Probenecid and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Sulopenem Etzadroxil/Probenecid in uncomplicated Urinary Tract Infection.
• Our in-depth analysis of the forecasted sales data of Sulopenem Etzadroxil/Probenecid from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Sulopenem Etzadroxil/Probenecid in uncomplicated Urinary Tract Infection.

Key Questions

• What is the product type, route of administration and mechanism of action of Sulopenem Etzadroxil/Probenecid?
• What is the clinical trial status of the study related to Sulopenem Etzadroxil/Probenecid in uncomplicated Urinary Tract Infection and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Sulopenem Etzadroxil/Probenecid development?
• What are the key designations that have been granted to Sulopenem Etzadroxil/Probenecid for uncomplicated Urinary Tract Infection?
• What is the forecasted market scenario of Sulopenem Etzadroxil/Probenecid for uncomplicated Urinary Tract Infection?
• What are the forecasted sales of Sulopenem Etzadroxil/Probenecid in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available in uncomplicated Urinary Tract Infection and how are they giving competition to Sulopenem Etzadroxil/Probenecid for uncomplicated Urinary Tract Infection?
• Which are the late-stage emerging therapies under development for the treatment of uncomplicated Urinary Tract Infection?